Your session is about to expire
← Back to Search
Denosumab for Multiple Myeloma
Study Summary
This trial will test if a drug called denosumab is safe and effective in treating people with a condition called smoldering multiple myeloma, which could turn into the cancer multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 4 trial • 37 Patients • NCT04026256Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have used IV bisphosphonates before or during the study.I am fully active and can carry on all my pre-disease activities without restriction.I have or had bone disease in my jaw.I have been using prescription oral fluorides or bisphosphonates for more than 3 months in the last 2 years.I take more than 10mg of prednisone or similar medication daily.I have had recent dental surgery that hasn't fully healed.I am 18 years old or older.I know the specific reason for my bone thinning or weakening.Your vitamin D level must be 30 ng/mL or higher after treatment.You are expected to live for more than 12 months.I am willing and able to follow the study's treatment and visit schedule.I have been diagnosed with smoldering multiple myeloma.I can take daily calcium and vitamin D supplements without issues.I need oral surgery or a tooth extraction due to a dental condition.I plan to undergo dental surgery while in the study.My organs are functioning normally.I have previously received denosumab treatment.I have symptoms from my multiple myeloma.I am of any ethnicity or racial background.
- Group 1: Denosumab
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
When was Denosumab cleared by the FDA?
"Since Phase 2 trials only have data supporting safety and no data regarding efficacy, denosumab was given a score of 2."
Yes, can you please tell us about some of the other research studies that have used Denosumab?
"Denosumab is being researched in 49 studies, with 13 of those research projects at Phase 3. The large majority of these trials are based in Nedlands, Western Australia; however, there are 539 locations running these Denosumab trials globally."
Are we still enrolling people in this experiment?
"The clinical trial in question is no longer recruiting patients, based on the information available on clinicaltrials.gov. This specific study was posted on April 19th, 2019 and updated for the last time on October 3rd, 2022. There are 877 other trials currently enrolling patients."
Could you explain what conditions are helped by Denosumab?
"Denosumab is used to target bones and bone marrow. It can also help with other issues such as skeletally mature, androgens, malignant neoplasms."
How many people are being asked to participate in this research project?
"This trial is not admitting patients at the moment. The most recent update was on October 3rd, 2022 and it was first posted April 19th, 2019. However, there are 828 other trials for smoldering multiple myeloma and 49 involving Denosumab that are currently enrolling patients."
Share this study with friends
Copy Link
Messenger